RxP Licensure & Registration Roadmap
At a glance: six-stage pathway
• 1 Prepare and submit the conditional certificate application
• 2 Obtain Board approval and an approved supervisory plan
• 3 Obtain NM controlled-substance registration, then federal DEA registration
• 4 Register for the New Mexico Prescription Monitoring Program (PMP)
• 5 Complete and document two-year conditional supervised practice
• 6 Apply for the full prescription certificate and complete peer review
PREPARING TO APPLY
Regulatory requirements — 16.22.23.8 and 16.22.24.8 NMAC. Confirm an active unrestricted New Mexico
psychologist license and qualifying psychopharmacology education. The conditional application
includes:
• Evidence of qualifying postdoctoral psychopharmacology education;
• Training director and supervisor certification of the 80-hour clinical assessment/pathophysiology
practicum;
• Training director and supervisor certification of the 400-hour clinical practicum treating at least 100
patients with mental disorders;
• Evidence of passing the Psychopharmacology Examination for Psychologists (PEP);
• Board-form supervisory plan signed by applicant and supervising clinician;
• Required malpractice coverage (at least $1 million per occurrence / $3 million aggregate under
16.22.24.9), application fee, and evidence of three-hour NM laws-and-rules training.
• The Trust offers professional liability insurance for psychologists, including RxP coverage in
approved states. Applicants should confirm that their policy specifically covers prescribing
activities in New Mexico, meets the required limits, and is effective for the relevant period.
• APPLY: The Trust Professional Liability Insurance
• REVIEW: Coverage Options and Policy Details
• For application assistance or questions about RxP coverage, contact The Trust at 877-637-
9700.
Practical note. The three-hour New Mexico laws/rules training is separate from the federal DEA
substance-use-disorder training/attestation discussed below. Confirm current SPA-NM or NMPA access,
posttest, and completion certificate procedures.
READ: education and eligibility rule
READ: conditional application and supervision rule
Regulatory requirements — 16.22.24.8–.10. The Board must approve the supervisory plan before the
conditional certificate is issued. The rule states that applicants are notified in writing within 60 days
whether the application and plan are accepted or rejected. Once approved, follow the prescribed
notification, supervision, and patient-consent requirements.
Recommended practice. Agree with the primary supervisor early on record access, case review,
scheduling, coverage, and how supervision and patient logs will be maintained.
Do not confuse pre-certificate clinical training with the subsequent two-year conditional period.
3. State controlled-substance and DEA registrations
New Mexico Board of Pharmacy
After conditional authority is granted, apply for the appropriate practitioner controlled-substance
registration through the current Board of Pharmacy process. Use the 2023 PDF as a reference only and
confirm whether the online process or forms have changed. VIEW: NM practitioner controlled-
substance application (2023 PDF)
Member experience, not general authorization. Dr. Michael Schwartz reports that his March 2026 state
application and certificate included schedules 2, 2N, 3, 3N, 4, and 5. This supersedes the earlier
anecdotal 2N/3N/4/5 example as a recent individual experience; it does NOT establish which schedules
every RxP should request. Confirm schedules and scope directly with the Board of Pharmacy.
Federal DEA
After obtaining the required state authority, complete the appropriate DEA application. Verify the correct
practitioner category, practice address, and schedules; federal registration does not expand state
prescribing authority. DEA describes a one-time training/credentialing/education attestation concerning
substance-use disorders for covered practitioners at their first applicable registration or renewal; the
often-mentioned “eight-hour course” is one way to satisfy this, not necessarily a separate universal
course requirement.
OPEN: DEA registration applications and guidance
READ: DEA training and registration FAQ
Member tip. Dr. Schwartz credits supervisor Dr. Christina Vento with walking him through pharmacy and
DEA applications, the DEA-related training requirement, and basic life support preparation. Treat BLS as a
useful onboarding question—not a confirmed universal NM RxP licensing prerequisite.
4. PMP enrollment and operational readiness
The NM PMP states that practitioner applicants must first have both NM controlled-substance registration
and a federal DEA registration. Complete account creation, email verification, identity documentation,
required training, and approval. Its guidance notes that approval may take up to two weeks.
REGISTER: NM Prescription Monitoring Program
Before issuing controlled-substance prescriptions, verify applicable electronic-prescribing (EPCS)
requirements, PMP-use rules, workplace privileges, pharmacy workflows, and insurance/credentialing
obligations. These operational steps may vary by setting.
5. Practicing under conditional authority
Core rules — 16.22.20, .21, .24 and .27 NMAC. The certificate is the beginning of a supervised clinical
practice period, not the end of the licensing process.
• Supervision: follow the Board-approved plan. The published 16.22.24.10 text specifies at least four
hours of one-to-one supervision monthly and states that supervision should total at least 46 hours per
year, subject to its modification provisions. Confirm any operative amendments before publication.
• Records: supervising clinicians must have access to and review the records for the cases they
supervise; maintain signed patient and supervision logs contemporaneously.
• Patients: disclose conditional status and the supervisor’s name and role; obtain informed consent
and appropriate releases.
• Collaboration: obtain authorization to communicate with the primary treating health care practitioner;
16.22.20.8 requires written notice within 24 hours after issuing a prescription and documented
ongoing collaboration.
• Scope: prescribe only within competence and the authorized psychotropic scope; follow the limits of
practice, formulary, laboratory, and controlled-substance rules.
• Notifications: 16.22.24.10 addresses notification to the NM Medical Board within 30 days after
supervisory-plan approval and changes in supervisors.
READ: health care practitioner collaboration
READ: limits of practice
READ: authorized formulary
6. Full prescription certificate and peer review
16.22.25.8 describes an application window beginning no sooner than 60 days and no later than 10 days
before conditional-certificate expiration. Confirm timing directly with the Board. The application includes
supervisor certification, insurance evidence, a signed patient log, and a signed supervision log.
Under 16.22.25.9, an independent panel reviews at least 10 randomly selected patient charts. The rule
specifies elements including history, mental status and differential diagnosis, risk factors, allergies,
medication list, consent, labs, diagnosis, dosing, treatment/outcomes, progress notes, follow-up, and
interprofessional collaboration. The applicant is responsible for obtaining charts for review.
Recommended practice. Arrange durable, lawful access to clinical charts and complete
contemporaneous documentation throughout the two-year period. Do not wait until the application
window to reconstruct logs or obtain record access.
READ: full certificate and peer-review rule
Maintaining authority: continuing education and renewal
16.22.9.8 specifies 60 CPE hours every two years for conditional and unrestricted prescribing
psychologists, including 40 hours in psychopharmacology or psychopharmacotherapy. Part 29 addresses
prescribing-certificate renewal; verify current deadlines and insurance documentation.
READ: continuing professional education
READ: prescribing certificate renewal
Core New Mexico RxP Regulations
Title 16, Chapter 22 — Psychologists and Psychologist Associates. Select each linked part to read the
official rule. These are principal provisions, not an exhaustive list of applicable laws.
Preparing to apply: Eligibility, education, application documents, and fees — Part 13 · Part 23 · Part 24
Obtaining conditional authority: Application review, approval, and supervision — Part 22 · Part 24
Practicing under conditional authority: Collaboration, limits of practice, supervision, formulary, and
PMP — Part 20 · Part 21 · Part 24 · Part 27 · Part 30
Transitioning to full authority: Patient and supervision logs, peer review, and certification — Part 25
Maintaining prescribing authority: Continuing education, certificate renewal, and PMP obligations —
Part 9 · Part 29 · Part 30
Additional supporting regulations. The selections above are not exhaustive. Other applicable provisions
address licensure, ethics, fees, complaints, and specialized eligibility.
View the complete Title 16 directory
Open items for member and regulatory verification
• Confirm all current Board application portals, forms, fees, and the approved three-hour NM
laws/rules training access and certificate process.
• Confirm whether all six controlled-substance schedules are appropriate for conditional RxPs, and
how applicants should select them.
• Confirm the operative supervision-hour standard and whether pending amendments have taken
effect; reconcile the published 46-hour language with any proposed changes.
• Confirm DEA MATE attestation pathways, any BLS/CPR requirements imposed by specific facilities,
and EPCS/PMP practice obligations.
• Confirm peer-review logistics, Board-approved logs, and records-access expectations; assign an SPA-
NM resource owner and next review date.
Link review note (Nov. 6, 2026): SRCA rule pages, the 2023 pharmacy PDF, NM PMP registration, and DEA
registration/FAQ pages were located through live web retrieval. Some agency pages intermittently block
automated access; users should confirm live navigation before publication. Other supporting rules and
agency-specific requirements should be reviewed before public release.
